CONCLUSION: There is no conclusive evidence that antipsychotic medication that raises prolactin levels increases the risk of breast cancer. Nevertheless, clinicians should always be cautious about prescribing antipsychotics for breast cancer patients. In our view, clinicians should always treat breast cancer risk factors as efficiently as possible, particularly when attending to patients who have schizophrenia.
Related topics
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Relationship between Prolactin, Breast cancer risk, and Antipsychotics in patients with Schizophrenia | 6 | 1330 | January 2, 2018 | |
| Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland | 1 | 231 | August 31, 2021 | |
| Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case-Control Database Study | 0 | 93 | April 30, 2024 | |
| Antipsychotics and the risk of breast cancer in women with schizophrenia | 0 | 234 | November 5, 2021 | |
| 'Prolactin-increasing' antipsychotics tied to breast cancer in female schizophrenics | 0 | 207 | October 15, 2021 |